Sales engine inflection arrives: contract sales +29%, VPG +30% — but credit and leverage still gate the rerating

What happened

Q3 2026 results show contract sales up 29% year over year to $565 million and volume per guest up 30% to $4,822, a sharp reversal from last year's declines. This directly addresses the key concern in the prior DeepValue report, where 3Q25 VPG was down 5% and contract sales down 4%. The improvement suggests management's FICO-based lead screening, incentive realignment, and owner-arrival restoration are finally converting into higher tour monetization. However, the prior risk framework still applies: leverage above 5.5x, modernization cash costs, and sales-reserve lag could cap equity upside even if top-line sales recover. Investors must verify that the sales surge is accompanied by EBITDA margin recovery and free cash flow generation, not just revenue growth.

Implication

The 29% contract sales growth and 30% VPG increase are exactly the inflection the WAIT thesis required, suggesting the sales engine fix is working. If 4Q26 and 1H27 sustain positive VPG and margin expansion, the base-case value of $62 may be too low and the stock could re-rate toward the bull case of $85. However, investors must confirm that higher contract sales are not being driven by looser underwriting or unsustainable incentives, and that the sales reserve is finally being released as delinquencies improve. Leverage and modernization spending remain the biggest swing factors: if ABS access stays open and cost savings materialize, free cash flow could inflect sharply. Until those are evidenced, a prudent approach is to hold existing positions and add only on confirmation that the sales recovery translates into durable earnings and debt reduction.

Thesis delta

The thesis shifts from 'wait for KPI stabilization' to 'stabilization has arrived, but viability now hinges on profitability and balance sheet normalization.' The Q3 2026 results remove the primary bear case of persistent VPG declines, but they do not yet prove the company can convert sales growth into free cash flow. As a result, the investment case improves from WAIT to a cautious BUY on confirmation, with the next checkpoint being 4Q26 margin and cash flow.